VICTORIA MOJIBOLA: Open Payments
NPI 1841789146 · TOWSON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,146 in 76 payments from 10 companies in 2025. Trend: 2023 $1,285 · 2024 $1,427 · 2025 $2,146
Food & beverage: $2,018Education: $128
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 20 | $728 |
| Vanda Pharmaceuticals Inc. | 8 | $242 |
| ABBVIE INC. | 11 | $235 |
| E.R. Squibb & Sons, L.L.C. | 5 | $185 |
| Teva Pharmaceuticals USA, Inc. | 4 | $162 |
| Janssen Pharmaceuticals, Inc | 8 | $154 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $139 |
| Supernus Pharmaceuticals, Inc. | 7 | $124 |
| Alkermes, Inc. | 4 | $93 |
| Otsuka America Pharmaceutical, Inc. | 3 | $85 |
Products named: INGREZZA, VRAYLAR, COBENFY, HETLIOZ, CAPLYTA, Qelbree, INVEGA SUSTENNA, FANAPT.
Industry payments across MD — which companies pay providers there.
